Getting Latino representation in COVID-19 vaccine trials

Dr. Katya Corado is leading the phase 3 trial of the Oxford University-AstraZeneca COVID-19 vaccine.
4:20 | 09/25/20

Coming up in the next {{countdown}} {{countdownlbl}}

Coming up next:

{{nextVideo.title}}

{{nextVideo.description}}

Skip to this video now

Now Playing:

{{currentVideo.title}}

Comments
Related Extras
Related Videos
Video Transcript
Transcript for Getting Latino representation in COVID-19 vaccine trials
See results at botoxcosmetic.com Minority groups especially the latinx community have been disproportionately impacted by covid-19. Now researchers are determined to make sure those most at risk are part of the effort to fight the deadly virus. Joining us now to discuss the covid-19 vaccine trial is Dr. Katya Corado. Thank you so much for being here. You're with that investigative team at the institute, this's leading the phase three of the astrazeneca oxford trial, for the vaccine that was paused because a participant had an adverse reaction. Where are we, can you give us an update? With any trial, when there's a serious event, the trial is pause. The pause allows the investigators to fully understand if that adverse reaction was due to the trial, was due to an outside event or due to a pre-existing medical condition, all the sites around the U.S. Are working closely with the fda to see when it's safe to open again, right now, we don't have an open date quite yet. And tell me how critical it is, do you worry about a vaccine trial that does not include enough members of the minority groups that are so disproportionately impacted, tell us why it's so important to have these minority groups a part of these vaccine trials? If we don't have a presentation of latinx or black communities in our vaccine trials, there will be less confidence of how that vaccine works in those populations. As you know, covid-19 has disproportionately affected communities of color and so, it's so important to have these communities represented in the vaccine trials so we know exactly how they will respond. Do you have the representation you want in this particular trial that gives you confidence and also, explain why it's been historically so difficult to get minority groups involved as participants in these trials? We can't ignore the complex relationship that exists between communities of color and the medical community, historically, there's been a lot of misunderstanding and a lot of mistrust and that is understandable. Part of that I believe is because there's been historically lack of representation of people in color in positions like investigators like I'm doing myself now, so it's of critical importance of someone like myself, so I can reach out and explain why the trial is so important and to calm some fears, so that's why we're trying very hard for this particular study to have involvement of communities that are most at risk. We just had governor Lamont on from Connecticut. And governor Cuomo here in new York. To hear governors say, once these trials are done and once these vaccines are approve, we're going to put them their our own process, but you also mentioned the idea of a mistrust, when you hear that states are now going to go back and do their own work on top of the work you're doing, good idea? I think it's always a wonderful idea to make sure that something is safe. I do understand that there's been a lot of fear about the term "Warp speed" and a lot of fear that we have been cutting corners. What has been actually happening is that the vaccine has been working through the phases that it has to work through just like any other vaccine, we've gone through phase one, phase two, now in phase three is when we examine a vaccine will be helpful in the population that need it most. I understand the fear and the concern, I think everyone should look at the data if possible and make the decisions. We believe that we're doing the work appropriately and we hope that the community also believes that. Dr. Corado, thank you so much for the work you've been doing. You're going at historic speed but you're not cutting corners. Thank you so much for having me. Thank you. Have a wonderful day. T.J., lot more ahead here on

This transcript has been automatically generated and may not be 100% accurate.

{"duration":"4:20","description":"Dr. Katya Corado is leading the phase 3 trial of the Oxford University-AstraZeneca COVID-19 vaccine.","mediaType":"default","section":"ABCNews/GMA","id":"73245391","title":"Getting Latino representation in COVID-19 vaccine trials","url":"/GMA/GMA3/video/latino-representation-covid-19-vaccine-trials-73245391"}